Target of action of tocilizumab

Tocilizumab (tocilizumab) targets the human cytokine interleukin-6 (IL-6). IL-6 is a cytokine that plays a key role in inflammatory responses and immune regulation. It participates in multiple immune and inflammatory processes, including regulating inflammatory responses, promoting B cell proliferation and differentiation, affecting T cell activation, and regulating the synthesis of C-reactive protein in the liver.

Tocilizumab blocks the IL-6 signaling pathway by binding toIL-6, thereby inhibiting the biological activity of IL-6. This can reduce inflammatory responses, improve symptoms of autoimmune diseases, and have a therapeutic effect on related diseases. It should be noted that since tocilizumab mainly acts on IL-6, the patient's condition and safety need to be carefully monitored when using it to ensure reasonable and effective drug application. Tocilizumab is generally given by doctors by intravenous or subcutaneous injection according to the patient's specific conditions and disease needs.

TocilizumabThe original drug has been launched in China and has been included in the medical insurance. Due to its short time on the market, the second-line treatment of systemic juvenile idiopathic arthritis is still limited to traditional treatments for rheumatoid arthritisDMARDs To treat patients whose disease activity has decreased by less than 50% in 3 to 6 months, Tocilizumab injection can only be used as directed by the doctor. Its price is around RMB 8,600, which is relatively expensive. The price of the European version of tocilizumab original drug available overseas is around around RMB 14,000 (the price may fluctuate due to the exchange rate). The ingredients and efficacy of the two drugs are basically the same. Currently, there are no generic drugs produced and marketed overseas, and patients can choose by themselves.